

12W



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

re application of: Alvaro et al.

Serial No.: 10/502,255

Group Art Unit: 1614

File Date: March 28, 2005

Examiner:

For: Piperidine Derivatives

Director of the U.S. Patent and Trademark Office  
P.O. Box 1450  
Alexandria, VA 22313-1450

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

- ☒ Copies of the references are enclosed: Ref. 48-87  
☐ Copies of the references were submitted in parent application \_\_\_\_\_ (37 CFR 1.98(d))  
☐ A copy of the International Search Report which issued on International Application No. \_\_\_\_\_ is submitted herewith. All of the publications cited in the International Search Report are listed on the attached form PTO-1449 and Applicants understand that copies have been supplied to the U.S. Patent Office by the International Bureau.

- A. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).

OR

- ☐ The Information Disclosure Statement submitted herewith is being filed before the mailing of a first office action or after the filing of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).

- B. ☐ The Information Disclosure Statement transmitted herewith is being filed **after** three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but **before** the mailing date of either:

- (1) a final action under § 1.113 or
- (2) a notice of allowance under § 1.311, whichever occurs first.

- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

- ☐ Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$180.00).

- C. ☐ The Information Disclosure Statement transmitted herewith is being filed **after** a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which Issued on International Publication No.


In accordance with the requirements of 37 CFR 1.97(d):

- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ Applicant hereby petitions for the consideration of the accompanying Information Disclosure Statement. 37 CFR 1.97(d)(ii).
- ☐ The petition fee set forth in § 1.17(i)(1) (\$130.00) is submitted herewith.

☒ Please charge any required fees to Deposit Account No.07-1392.

☐ A duplicate copy of this paper is attached.

Respectfully Submitted,



Lorie Ann Morgan


Registration No. 38,181

Date: 25 May 2005  
GlaxoSmithKline  
Corporate Intellectual Property  
5 Moore Drive, P.O. Box 13398  
Research Triangle Park, NC 27709-3398  
Telephone: (919) 483-8222  
Facsimile: (919) 483-7988

**CERTIFICATE OF MAILING (37 CFR 1.8)**

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date: 5/25/05

  
Valerie L. Phillips

<b>FORM PTO-1449</b> <b>INFORMATION DISCLOSURE STATEMENT</b>				<b>ATTORNEY DOCKET NO.</b> PI4747USW		<b>SERIAL NO.</b> 10/502,255	
				<b>APPLICANT:</b> Alvaro et al.			
				<b>FILING DATE:</b>		<b>GROUP</b> 1614	
<b>U.S. PATENT DOCUMENTS</b>							
Examiner Initials		Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
	1	RE 37,886	Oct. 15, 2002	Janssens et al.			
	2	4,087,424	May 2, 1978	Saikawa et al.			
	3	4,110,327	Apr. 29, 1978	Saikawa et al.			
	4	4,112,090	Sept. 5, 1978	Saikawa et al.			
	5	4,219,554	Aug. 26, 1980	Saikawa et al.			
	6	4,308,387	Dec. 29, 1981	Bjork et al.			
	7	4,327,097	Apr. 27, 1982	Saikawa et al.			
	8	4,379,152	Apr. 5, 1983	Saikawa et al.			
	9	4,410,522	Oct. 18, 1983	Saikawa et al.			
	10	5,028,610	July 2, 1991	Hirai et al.			
	11	5,109,014	Apr. 28, 1992	Jacobson et al.			
	12	5,334,606	Aug. 2, 1994	MacLeod et al.			
	13	5,348,955	Sept. 20, 1994	Greenlee et al.			
	14	5,360,820	Nov. 1, 1994	Hagan et al.			
	15	5,464,788	Nov. 7, 1995	Bock et al.			
	16	5,538,982	July 23, 1996	Hagan et al.			
	17	5,563,127	Oct. 8, 1996	Amparo et al.			
	18	5,576,317	Nov. 19, 1996	Gonsalves et al.			
	19	5,696,123	Dec. 9, 1997	Dollinger et al.			
	20	5,698,538	Dec. 16, 1997	Amparo et al.			
	21	5,708,006	Jan. 13, 1998	Dollinger et al.			
	22	5,710,169	Jan. 20, 1998	Russell et al.			
	23	5,716,942	Feb. 10, 1998	Dorn et al.			
	24	5,756,504	May 26, 1998	Bock et al.			
	25	5,814,636	Sept. 29, 1998	Katano et al.			
	26	5,859,015	Jan. 12, 1999	Graham et al.			
	27	5,883,096	Mar. 16, 1999	Lowe et al.			
	28	5,935,951	Aug. 10, 1999	Ofner et al.			
	29	5,952,315	Sept. 14, 1999	Baker et al.			
	30	5,977,104	Nov. 2, 1999	Baker et al.			
	31	5,985,881	Nov. 16, 1999	Dollinger et al.			
	32	5,998,444	Dec. 7, 1999	Russell et al.			
	33	6,037,352	Mar. 14, 2000	Lowe et al.			
	34	6,057,323	May 2, 2000	Zhang et al.			
	35	6,090,807	July 18, 2000	Hellendahl et al.			
	36	6,114,315	Sept. 5, 2000	Baker et al.			
	37	6,117,855	Sept. 12, 2000	Carlson et al.			
	38	6,147,083	Nov. 14, 2000	Russell et al.			
	39	6,191,135	Feb. 20, 2001	Dollinger et al.			
	40	6,191,139	Feb. 20, 2001	Hagan et al.			
	41	6,197,772	March 6, 2001	Janssens et al.			
	42	6,235,732	May 22, 2001	Dollinger et al.			
	43	6,288,068	Sept. 11, 2001	Lowe et al.			
	44	6,319,953	Nov. 20, 2001	Carlson et al.			
	45	6,521,621	Feb. 18, 2003	Janssens et al.			
	46	6,642,240	Nov. 2003	Alvaro et al.			
	47	US 20020103205	Aug. 1, 2002	Lowe et al.			

Continue on page

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT				ATTORNEY DOCKET NO. PI4747USW		SERIAL NO. 10/502,255	
				APPLICANT: Alvaro et al.			
				FILING DATE:		GROUP 1614	
FOREIGN PATENT DOCUMENTS							
		Document Number	Publication Date	Country	Class	Subclass	Translation Yes   No
	48	DE 2519400	Apr. 19, 1978	DE			Abstract only
	49	EP 0532456	Mar. 17, 1993	EUROPE			
	50	EP 0655442	May 31, 1995	EUROPE			
	51	EP 0721941	July 17, 1996	EUROPE			
	52	EP 287734	Oct. 15, 1987	EUROPE			
	53	EP 293532	Oct. 15, 1987	EUROPE			
	54	EP 718287	Dec. 19, 1995	EUROPE			Abstract only
	55	GB 1508062	Apr. 28, 1975	GB			
	56	JP 57/118587	July 23, 1982	Japan			Abstract only
	57	WO 01/25219	Apr. 12, 2001	WIPO			
	58	WO 02/032867	Apr. 25, 2002	WIPO			
	59	WO 02/057233	July 25, 2002	WIPO			
	60	WO 04/033428	Apr. 22, 2004	WIPO			
	61	WO 92/16211	Oct. 1, 1992	WIPO			
	62	WO 95/00498	Jan. 5, 1995	WIPO			
	63	WO 95/25443	Sept. 28, 1995	PCT			
	64	WO 96/02503	Feb. 1, 1996	WIPO			Abstract only
	65	WO 96/03378	Feb. 8, 1996	WIPO			Abstract only
	66	WO 96/10562	Apr. 11, 1996	WIPO			
	67	WO 96/14844	May 23, 1996	WIPO			
	68	WO 96/20173	July 4, 1996	WIPO			
	69	WO 97/16440	May 9, 1997	WIPO			
	70	WO 97/24324	July 10, 1997	WIPO			
	71	WO 97/32865	Sept. 12, 1997	WIPO			
	72	WO 97/36592	Oct. 9, 1997	WIPO			
	73	WO 97/36593	Oct. 9, 1997	WIPO			
	74	WO 97/36888	Oct. 9, 1997	WIPO			
	75	WO 97/36889	Oct. 9, 1997	WIPO			
	76	WO 98/01133	Jan. 15, 1998	WIPO			Abstract only
	77	WO 98/20001	May 14, 1998	WIPO			
	78	WO 98/57954	Dec. 23, 1998	WIPO			
	79	WO 99/09985	Mar. 4, 1999	WIPO			
	80	WO 99/26921	June 3, 1999	WIPO			
	81	WO 99/37304	July 29, 1999	WIPO			
Continue on page							
OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)							
	82	Challet, E., et al. Neuropharmacology 40(3):408-415 (2001).					
	83	Davis, David T., "Synthesis A. Biological Activity of a Series of Piperazin-2, 3-Biones," Journal of Antibiotics, Vol. XLII, No. 3, 1989, pp. 367-73.					
	84	Megens, A., et al. J. Pharmacology and Experimental Therapeutics 302(2):696-709 (2002).					
	85	Pacher, P., et al. "Review of Cardiovascular Effects of Fluoxetine, A Selective Serotonin Reuptake Inhibitor, Compared to Tricyclic Antidepressants." Current Medicinal Chemistry, 5, pgs 381-390, 1998.					
	86	Romerio, et al. Clinical Pharmacology and Therapeutics 66(5):522-527 (1999).					
	87	Rupniak et al. "Differential inhibition of foot tapping and chromodacyorrhoea in gerbils by CNS penetrant and non-penetrant tachykinin NK <sub>1</sub> receptor antagonists." European Journal of Pharmacology 265:179-183 (1994).					
EXAMINER					DATE CONSIDERED		
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.							